![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
July 7, 2021
ECOG-ACRIN has established a Task Force on Advancement for Women under the leadership of Barbara Burtness, MD of Yale University
July 7, 2021
Recent ECOG-ACRIN trial updates and results
July 7, 2021
This phase II/III study is comparing the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery
July 7, 2021
May 28, 2021
Virtual Spring 2021 Group Meeting generates record attendance; screening and genomic trials return to full activity
May 28, 2021
This phase II study, led by Dr. Kim Reiss Binder, is exploring whether the addition of maintenance PARP inhibition for BRCA- or PALB2-mutated pancreatic cancer improves outcomes
May 28, 2021
In an annual evaluation, 22 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
May 28, 2021
The EA8185 phase II trial is the first prospective study exclusively for patients with lymph node positive bladder cancer
May 28, 2021
April 27, 2021
With cherry blossoms finished weeks ago, and fragrant magnolia blooms littering paths, Philadelphia is well into spring, and that means it must be time for an ECOG-ACRIN Group Meeting
April 27, 2021
Most of us are virtual meeting pros by now—and though many miss the connection and energy of in-person events, there is something to be said for attending sessions in sweatpants, a favorite coffee mug in hand
April 27, 2021
A Standing Main Member of ECOG-ACRIN since 2005